0001689548-26-000029
SEC filingPraxis Precision Medicines, Inc. reported a net loss of $303.3 million for fiscal year 2025, with no collaboration revenue. The company incurred significant operating expenses totaling $326.2 million, primarily driven by research and development costs of $267.1 million and general and administrative expenses of $59.1 million. Other income of $22.9 million partially offset the operating loss. The company's balance sheet remains strong with total assets of $937.9 million, including $357.3 million in cash and cash equivalents and $568.8 million in marketable securities. Total liabilities were minimal at $59.8 million, resulting in stockholders' equity of $878.1 million. Cash flow from operations was negative $249.1 million, while financing activities provided $702.2 million primarily from stock offerings. The company's accumulated deficit increased to $1.14 billion, reflecting continued investment in research and development activities.
Praxis Precision Medicines, Inc. reported a net loss of $303.3 million for fiscal year 2025, with no collaboration revenue generated during the period. The company's operating loss was $326.2 million, primarily driven by research and development expenses of $267.1 million and general and administrative expenses of $59.1 million. Other income of $22.9 million, primarily from interest on marketable securities, partially offset the operating loss. The company reported a basic and diluted net loss per share of $13.00, based on weighted average common shares outstanding of 22.5 million. The company's financial performance reflects its continued investment in research and development activities as a clinical-stage biopharmaceutical company.
No revenue was reported for fiscal year 2025. The company's income statement shows collaboration revenue of $0, indicating that the company has not yet generated commercial revenue from its product candidates. As a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, Praxis Precision Medicines is in the research and development phase and has not yet commercialized any products. The absence of revenue is consistent with the company's stage of development and its focus on advancing its pipeline through clinical trials.
The company reported an operating loss of $326.2 million for fiscal year 2025, with research and development expenses representing approximately 82% of total operating expenses. General and administrative expenses accounted for the remaining 18% of operating expenses. The company's cost structure is heavily weighted toward research and development, reflecting its focus on advancing multiple clinical programs. With no revenue generated during the period, traditional margin calculations (gross margin, operating margin) are not applicable. The company's accumulated deficit increased to $1.14 billion as of December 31, 2025, reflecting cumulative losses since inception.
The company used $249.1 million in cash from operating activities during fiscal year 2025, primarily due to the net loss of $303.3 million, partially offset by non-cash adjustments including stock-based compensation of $33.9 million. Investing activities used $311.1 million, primarily for purchases of marketable securities totaling $623.8 million, partially offset by maturities of $312.7 million. Financing activities provided $702.2 million, with $691.0 million from stock offerings net of issuance costs. The balance sheet shows total assets of $937.9 million, including $357.3 million in cash and cash equivalents and $568.8 million in marketable securities. Total liabilities were $59.8 million, resulting in stockholders' equity of $878.1 million and a strong liquidity position.
The filing does not provide specific forward-looking guidance or management projections for future periods. As a clinical-stage biopharmaceutical company, Praxis Precision Medicines continues to focus on advancing its pipeline of product candidates for central nervous system disorders. The company's strong balance sheet with $926.1 million in cash, cash equivalents, and marketable securities provides substantial resources to fund ongoing research and development activities. The company will need to successfully advance its clinical programs, obtain regulatory approvals, and eventually commercialize products to generate revenue and achieve profitability. Key risk factors include clinical trial outcomes, regulatory approvals, competition, and the ability to successfully commercialize products if approved.